

# The Role of Astrocytes in Multiple Sclerosis Progression

Frontiers in Neurology

6, 180

DOI: [10.3389/fneur.2015.00180](https://doi.org/10.3389/fneur.2015.00180)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Oligodendrocyte, Astrocyte, and Microglia Crosstalk in Myelin Development, Damage, and Repair. <i>Frontiers in Cell and Developmental Biology</i> , 2016, 4, 71.	1.8	292
2	The Role of Astrocytes in the Generation, Migration, and Integration of New Neurons in the Adult Olfactory Bulb. <i>Frontiers in Neuroscience</i> , 2016, 10, 149.	1.4	67
3	Viral Vector-Based Dissection of Marmoset GFAP Promoter in Mouse and Marmoset Brains. <i>PLoS ONE</i> , 2016, 11, e0162023.	1.1	20
4	Multiple Sclerosis and Obesity: Possible Roles of Adipokines. <i>Mediators of Inflammation</i> , 2016, 2016, 1-24.	1.4	170
5	Astrocytes in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1114-1124.	1.4	108
6	Acute axonal damage in three different murine models of multiple sclerosis: A comparative approach. <i>Brain Research</i> , 2016, 1650, 125-133.	1.1	38
7	Progressive multiple sclerosis: from pathogenic mechanisms to treatment. <i>Brain</i> , 2017, 140, aww258.	3.7	311
8	Regulation of astroglia by gonadal steroid hormones under physiological and pathological conditions. <i>Progress in Neurobiology</i> , 2016, 144, 5-26.	2.8	101
9	IL-17 induces MIP-1 $\alpha$ expression in primary mouse astrocytes via TRPC channel. <i>Inflammopharmacology</i> , 2016, 24, 33-42.	1.9	7
10	Regulatory effect of triiodothyronine on brain myelination and astrogliosis after cuprizone-induced demyelination in mice. <i>Metabolic Brain Disease</i> , 2016, 31, 425-433.	1.4	28
11	MicroRNA-19b-3p Modulates Japanese Encephalitis Virus-Mediated Inflammation via Targeting RNF11. <i>Journal of Virology</i> , 2016, 90, 4780-4795.	1.5	85
12	Sphingosine 1-phosphate signaling in astrocytes: Implications for progressive multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2016, 361, 60-65.	0.3	25
13	Effects of multiwalled carbon nanotubes on electrospun poly(lactide-co-glycolide)-based nanocomposite scaffolds on neural cells proliferation. , 2017, 105, 934-943.		13
14	Toll-like receptor signalling as a cannabinoid target in Multiple Sclerosis. <i>Neuropharmacology</i> , 2017, 113, 618-626.	2.0	37
15	Adenosine Triphosphate Metabolism Measured by Phosphorus Magnetic Resonance Spectroscopy: A Potential Biomarker for Multiple Sclerosis Severity. <i>European Neurology</i> , 2017, 77, 316-321.	0.6	21
16	Drug discovery for remyelination and treatment of MS. <i>Glia</i> , 2017, 65, 1565-1589.	2.5	41
17	Increased total sodium concentration in gray matter better explains cognition than atrophy in MS. <i>Neurology</i> , 2017, 88, 289-295.	1.5	40
18	Insights in pathogenesis of multiple sclerosis: nitric oxide may induce mitochondrial dysfunction of oligodendrocytes. <i>Reviews in the Neurosciences</i> , 2017, 29, 39-53.	1.4	38

#	ARTICLE	IF	CITATIONS
19	The effects of berberine on a murine model of multiple sclerosis and the SPHK1/S1P signaling pathway. <i>Biochemical and Biophysical Research Communications</i> , 2017, 490, 927-932.	1.0	13
20	Gestational Hypothyroxinemia Imprints a Switch in the Capacity of Astrocytes and Microglial Cells of the Offspring to React in Inflammation. <i>Molecular Neurobiology</i> , 2018, 55, 4373-4387.	1.9	5
21	Involvement of the IL-1 system in experimental autoimmune encephalomyelitis and multiple sclerosis: Breaking the vicious cycle between IL-1 $\beta$ and GM-CSF. <i>Brain, Behavior, and Immunity</i> , 2017, 62, 1-8.	2.0	41
22	Achievements and obstacles of remyelinating therapies in multiple sclerosis. <i>Nature Reviews Neurology</i> , 2017, 13, 742-754.	4.9	89
23	A mathematical model of cellular swelling in Neuromyelitis optica. <i>Journal of Theoretical Biology</i> , 2017, 433, 39-48.	0.8	3
24	Microsomal Prostaglandin E Synthase-1 Facilitates an Intercellular Interaction between CD4+ T Cells through IL-1 $\beta$ Autocrine Function in Experimental Autoimmune Encephalomyelitis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2758.	1.8	8
25	The Transcriptome of Type I Murine Astrocytes under Interferon-Gamma Exposure and Remyelination Stimulus. <i>Molecules</i> , 2017, 22, 808.	1.7	21
26	p21-Activated Kinase 4 Signaling Promotes Japanese Encephalitis Virus-Mediated Inflammation in Astrocytes. <i>Frontiers in Cellular and Infection Microbiology</i> , 2017, 7, 271.	1.8	18
27	Modulation of P2X7 Receptor during Inflammation in Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2017, 8, 1529.	2.2	53
28	A Refined Bead-Free Method to Identify Astrocytic Exosomes in Primary Glial Cultures and Blood Plasma. <i>Frontiers in Neuroscience</i> , 2017, 11, 335.	1.4	29
29	Does the Gut Microbiota Influence Immunity and Inflammation in Multiple Sclerosis Pathophysiology?. <i>Journal of Immunology Research</i> , 2017, 2017, 1-14.	0.9	52
30	Salutary effects of glibenclamide during the chronic phase of murine experimental autoimmune encephalomyelitis. <i>Journal of Neuroinflammation</i> , 2017, 14, 177.	3.1	25
31	The critical chemical and mechanical regulation of folic acid on neural engineering. <i>Biomaterials</i> , 2018, 178, 504-516.	5.7	31
32	astrocyte disruption of neurovascular communication is linked to cortical damage in an animal model of multiple sclerosis. <i>Glia</i> , 2018, 66, 1098-1117.	2.5	37
33	Evidence of progressive tissue loss in the core of chronic MS lesions: A longitudinal DTI study. <i>NeuroImage: Clinical</i> , 2018, 17, 1028-1035.	1.4	46
34	The Neuropathology of Progressive Multiple Sclerosis. , 2018, , 49-69.		2
35	What role does multiple sclerosis play in the development of untreatable painful conditions?. <i>Pain Management</i> , 2018, 8, 37-44.	0.7	9
36	Kolaviron protects the brain in cuprizone-induced model of experimental multiple sclerosis via enhancement of intrinsic antioxidant mechanisms: Possible therapeutic applications?. <i>Pathophysiology</i> , 2018, 25, 299-306.	1.0	32

#	ARTICLE	IF	CITATIONS
37	Cholinergic imbalance in lumbar spinal cord of a rat model of multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2018, 318, 29-35.	1.1	0
38	Voltage Gated Potassium Channel Kv1.3 Is Upregulated on Activated Astrocytes in Experimental Autoimmune Encephalomyelitis. <i>Neurochemical Research</i> , 2018, 43, 1020-1034.	1.6	18
39	Clonal Glial Response in a Multiple Sclerosis Mouse Model. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 375.	1.8	22
40	Endothelial Microsomal Prostaglandin E Synthetase-1 Upregulates Vascularity and Endothelial Interleukin-1 $\beta$ in Deteriorative Progression of Experimental Autoimmune Encephalomyelitis. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3647.	1.8	2
41	Targeting senescence to delay progression of multiple sclerosis. <i>Journal of Molecular Medicine</i> , 2018, 96, 1153-1166.	1.7	30
42	Serum GFAP as a biomarker for disease severity in multiple sclerosis. <i>Scientific Reports</i> , 2018, 8, 14798.	1.6	164
43	Impact of Glatiramer Acetate on B Cell-Mediated Pathogenesis of Multiple Sclerosis. <i>CNS Drugs</i> , 2018, 32, 1039-1051.	2.7	25
44	Human Induced Pluripotent Stem Cell-Derived Astrocytes Are Differentially Activated by Multiple Sclerosis-Associated Cytokines. <i>Stem Cell Reports</i> , 2018, 11, 1199-1210.	2.3	114
45	Specific Alterations in Astrocyte Properties via the GluA2-GAPDH Complex Associated with Multiple Sclerosis. <i>Scientific Reports</i> , 2018, 8, 12856.	1.6	9
46	Astrocyte Neuroprotection and Dehydroepiandrosterone. <i>Vitamins and Hormones</i> , 2018, 108, 175-203.	0.7	10
47	Laquinimod protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model. <i>Journal of Neuroinflammation</i> , 2018, 15, 183.	3.1	39
48	NLR-Dependent Regulation of Inflammation in Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2017, 8, 2012.	2.2	66
49	Microscale Architecture in Biomaterial Scaffolds for Spatial Control of Neural Cell Behavior. <i>Frontiers in Materials</i> , 2018, 5, .	1.2	16
50	Coagulation Factor XII Levels and Intrinsic Thrombin Generation in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2018, 9, 245.	1.1	23
51	Granulocyte-macrophage colony-stimulating factor as a mediator of autoimmunity in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2018, 323, 1-9.	1.1	15
52	KIAA1199 expression and hyaluronan degradation colocalize in multiple sclerosis lesions. <i>Glycobiology</i> , 2018, 28, 958-967.	1.3	10
53	Blockade of sustained tumor necrosis factor in a transgenic model of progressive autoimmune encephalomyelitis limits oligodendrocyte apoptosis and promotes oligodendrocyte maturation. <i>Journal of Neuroinflammation</i> , 2018, 15, 121.	3.1	27
54	Increased expression of colony-stimulating factor-1 in mouse spinal cord with experimental autoimmune encephalomyelitis correlates with microglial activation and neuronal loss. <i>Glia</i> , 2018, 66, 2108-2125.	2.5	36

#	ARTICLE	IF	CITATIONS
55	Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis. <i>Annals of Neurology</i> , 2018, 84, 51-63.	2.8	38
56	Neuro-Immune-Endocrine Interactions in Multiple Sclerosis. <i>Advances in Neuroimmune Biology</i> , 2018, 7, 55-65.	0.7	3
57	Neurotoxic potential of reactive astrocytes in canine distemper demyelinating leukoencephalitis. <i>Scientific Reports</i> , 2019, 9, 11689.	1.6	13
58	Retinal pathology in experimental optic neuritis is characterized by retrograde degeneration and gliosis. <i>Acta Neuropathologica Communications</i> , 2019, 7, 116.	2.4	48
59	The Bu Shen Yi Sui Formula Promotes Axonal Regeneration via Regulating the Neurotrophic Factor BDNF/TrkB and the Downstream PI3K/Akt Signaling Pathway. <i>Frontiers in Pharmacology</i> , 2019, 10, 796.	1.6	12
60	Engineering biomaterial microenvironments to promote myelination in the central nervous system. <i>Brain Research Bulletin</i> , 2019, 152, 159-174.	1.4	17
61	The Potassium Channel Kv1.5 Expression Alters During Experimental Autoimmune Encephalomyelitis. <i>Neurochemical Research</i> , 2019, 44, 2733-2745.	1.6	6
62	High mobility group box 1 (HMGB1) protein in Multiple Sclerosis (MS): Mechanisms and therapeutic potential. <i>Life Sciences</i> , 2019, 238, 116924.	2.0	20
63	On elucidation of the role of mitochondria dysfunction and oxidative stress in multiple sclerosis. <i>Neurology and Clinical Neuroscience</i> , 2019, 7, 305-317.	0.2	6
64	Excitatory Amino Acid Transporters in Physiology and Disorders of the Central Nervous System. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5671.	1.8	97
65	Co-stimulation with IL-1 $\beta$ and TNF- $\alpha$ induces an inflammatory reactive astrocyte phenotype with neurosupportive characteristics in a human pluripotent stem cell model system. <i>Scientific Reports</i> , 2019, 9, 16944.	1.6	93
66	The Relationship Between Neuroimmunity and Bipolar Disorder: Mechanism and Translational Application. <i>Neuroscience Bulletin</i> , 2019, 35, 595-607.	1.5	19
67	Central nervous system targeted autoimmunity causes regional atrophy: a 9.4T MRI study of the EAE mouse model of Multiple Sclerosis. <i>Scientific Reports</i> , 2019, 9, 8488.	1.6	28
68	The effects of a combination of ion channel inhibitors on pathology in a model of demyelinating disease. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 34, 1-8.	0.9	6
69	The role of fatty acid binding protein 7 in spinal cord astrocytes in a mouse model of experimental autoimmune encephalomyelitis. <i>Neuroscience</i> , 2019, 409, 120-129.	1.1	19
70	Effect of mesenchymal stem cells on glial cells population in cuprizone induced demyelination model. <i>Neuropeptides</i> , 2019, 75, 75-84.	0.9	17
71	Nox2-dependent neuroinflammation in an EAE model of multiple sclerosis. <i>Translational Neuroscience</i> , 2019, 10, 1-9.	0.7	30
72	Unsupervised quantification of tissue immunofluorescence in animal models of multiple sclerosis "Instructions for use. <i>Journal of Neuroscience Methods</i> , 2019, 320, 87-97.	1.3	1

#	ARTICLE	IF	CITATIONS
73	Mechanisms of neurobehavioral abnormalities in multiple sclerosis: Contributions from neural and immune components. <i>Clinical Neurophysiology Practice</i> , 2019, 4, 39-46.	0.6	8
74	Mechanisms of Neurodegeneration and Axonal Dysfunction in Progressive Multiple Sclerosis. <i>Biomedicines</i> , 2019, 7, 14.	1.4	76
75	Remyelination Pharmacotherapy Investigations Highlight Diverse Mechanisms Underlying Multiple Sclerosis Progression. <i>ACS Pharmacology and Translational Science</i> , 2019, 2, 372-386.	2.5	28
76	Multiple Sclerosis: Destruction and Regeneration of Astrocytes in Acute Lesions. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 140-156.	0.9	28
77	Human Remyelination Promoting Antibody Stimulates Astrocytes Proliferation Through Modulation of the Sphingolipid Rheostat in Primary Rat Mixed Glial Cultures. <i>Neurochemical Research</i> , 2019, 44, 1460-1474.	1.6	8
78	Microglial modulation through colony-stimulating factor-1 receptor inhibition attenuates demyelination. <i>Glia</i> , 2019, 67, 291-308.	2.5	29
79	Astrocyte ablation induced by L-aminoadipate (L-AAA) potentiates remyelination in a cuprizone demyelinating mouse model. <i>Metabolic Brain Disease</i> , 2019, 34, 593-603.	1.4	31
80	The formation of a glial scar does not prohibit remyelination in an animal model of multiple sclerosis. <i>Glia</i> , 2019, 67, 467-481.	2.5	31
81	Participación de los astrocitos en la patogénesis de la esclerosis múltiple. <i>Neurología</i> , 2020, 35, 400-408.	0.3	7
82	Towards a comprehensive etiopathogenetic and pathophysiological theory of multiple sclerosis. <i>International Journal of Neuroscience</i> , 2020, 130, 279-300.	0.8	11
83	Roles of glial ion transporters in brain diseases. <i>Glia</i> , 2020, 68, 472-494.	2.5	43
84	Exercise in multiple sclerosis and its models: Focus on the central nervous system outcomes. <i>Journal of Neuroscience Research</i> , 2020, 98, 509-523.	1.3	27
85	“Prototypical” proinflammatory cytokine (IL-1) in multiple sclerosis: role in pathogenesis and therapeutic targeting. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 37-46.	1.5	16
86	Iron Metabolism in Oligodendrocytes and Astrocytes, Implications for Myelination and Remyelination. <i>ASN Neuro</i> , 2020, 12, 175909142096268.	1.5	73
87	A Score Based on NfL and Glial Markers May Differentiate Between Relapsing-Remitting and Progressive MS Course. <i>Frontiers in Neurology</i> , 2020, 11, 608.	1.1	25
88	Protection of Fecal Microbiota Transplantation in a Mouse Model of Multiple Sclerosis. <i>Mediators of Inflammation</i> , 2020, 2020, 1-13.	1.4	50
89	The role of astrocytes in multiple sclerosis pathogenesis. <i>Neurología (English Edition)</i> , 2020, 35, 400-408.	0.2	1
90	Anti-inflammatory and immune-modulatory impacts of berberine on activation of autoreactive T cells in autoimmune inflammation. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 13573-13588.	1.6	63

#	ARTICLE	IF	CITATIONS
91	Transplantation of induced neural stem cells (iNSCs) into chronically demyelinated corpus callosum ameliorates motor deficits. <i>Acta Neuropathologica Communications</i> , 2020, 8, 84.	2.4	21
92	Remodeling of the interstitial extracellular matrix in white matter multiple sclerosis lesions: Implications for remyelination (failure). <i>Journal of Neuroscience Research</i> , 2020, 98, 1370-1397.	1.3	29
93	Aberrant DNA methylation profile exacerbates inflammation and neurodegeneration in multiple sclerosis patients. <i>Journal of Neuroinflammation</i> , 2020, 17, 21.	3.1	46
94	Astrocyte- $\gamma$ cell crosstalk regulates region-specific neuroinflammation. <i>Glia</i> , 2020, 68, 1361-1374.	2.5	36
95	Astrocyte metabolism in multiple sclerosis investigated by 1-C-11 acetate PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 369-379.	2.4	15
96	Ethyl Pyruvate-Derived Transdifferentiation of Astrocytes to Oligodendrogenesis in Cuprizone-Induced Demyelinating Model. <i>Neurotherapeutics</i> , 2021, 18, 488-502.	2.1	8
97	A mathematical model of the multiple sclerosis plaque. <i>Journal of Theoretical Biology</i> , 2021, 512, 110532.	0.8	6
98	Primary neuron and astrocyte cultures from postnatal <i>Callithrix jacchus</i> : a non-human primate in vitro model for research in neuroscience, nervous system aging, and neurological diseases of aging. <i>GeroScience</i> , 2021, 43, 115-124.	2.1	1
99	Altered astrocytic function in experimental neuroinflammation and multiple sclerosis. <i>Glia</i> , 2021, 69, 1341-1368.	2.5	24
100	Intranasal anti-caspase-1 therapy preserves myelin and glucose metabolism in a model of progressive multiple sclerosis. <i>Glia</i> , 2021, 69, 216-229.	2.5	10
101	Astrocytes: a double-edged sword in neurodegenerative diseases. <i>Neural Regeneration Research</i> , 2021, 16, 1702.	1.6	74
102	Preclinical Therapy with Vitamin D3 in Experimental Encephalomyelitis: Efficacy and Comparison with Paricalcitol. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1914.	1.8	10
103	Increased Expression of Ephrins on Immune Cells of Patients with Relapsing Remitting Multiple Sclerosis Affects Oligodendrocyte Differentiation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2182.	1.8	4
104	m6A RNA Methylation in Systemic Autoimmune Diseases-A New Target for Epigenetic-Based Therapy?. <i>Pharmaceuticals</i> , 2021, 14, 218.	1.7	16
105	Mitochondrial Behavior in Axon Degeneration and Regeneration. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 650038.	1.7	37
106	Myelin Repair: From Animal Models to Humans. <i>Frontiers in Cellular Neuroscience</i> , 2021, 15, 604865.	1.8	21
107	BMSCs differentiated into neurons, astrocytes and oligodendrocytes alleviated the inflammation and demyelination of EAE mice models. <i>PLoS ONE</i> , 2021, 16, e0243014.	1.1	8
108	Specific Blockade of Bone Morphogenetic Protein-2/4 Induces Oligodendrogenesis and Remyelination in Demyelinating Disorders. <i>Neurotherapeutics</i> , 2021, 18, 1798-1814.	2.1	5

#	ARTICLE	IF	CITATIONS
109	Baicalein Delays H <sub>2</sub> O <sub>2</sub> -Induced Astrocytic Senescence through Inhibition of Senescence-Associated Secretory Phenotype (SASP), Suppression of JAK2/STAT1/NF- $\kappa$ B Pathway, and Regulation of Leucine Metabolism. <i>ACS Chemical Neuroscience</i> , 2021, 12, 2320-2335.	1.7	13
110	RGC-32 Acts as a Hub to Regulate the Transcriptomic Changes Associated With Astrocyte Development and Reactive Astrocytosis. <i>Frontiers in Immunology</i> , 2021, 12, 705308.	2.2	1
111	MANF Is Neuroprotective in Early Stages of EAE, and Elevated in Spinal White Matter by Treatment With Dexamethasone. <i>Frontiers in Cellular Neuroscience</i> , 2021, 15, 640084.	1.8	7
112	Expansion of chronic MS lesions is associated with an increase of radial diffusivity in periplaque white matter. <i>Multiple Sclerosis Journal</i> , 2022, 28, 697-706.	1.4	7
113	Potential of PINK1 and PARKIN Proteins as Biomarkers for Active Multiple Sclerosis: A Japanese Cohort Study. <i>Frontiers in Immunology</i> , 2021, 12, 681386.	2.2	12
114	Clinical and Paraclinical Biomarkers and the Hitches to Assess Conversion to Secondary Progressive Multiple Sclerosis: A Systematic Review. <i>Frontiers in Neurology</i> , 2021, 12, 666868.	1.1	13
115	What telomeres teach us about MS. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 54, 103084.	0.9	8
116	PARKIN modifies peripheral immune response and increases neuroinflammation in active experimental autoimmune encephalomyelitis (EAE). <i>Journal of Neuroimmunology</i> , 2021, 359, 577694.	1.1	8
117	Effect of CSF1R inhibitor on glial cells population and remyelination in the cuprizone model. <i>Neuropeptides</i> , 2021, 89, 102179.	0.9	9
118	RGC-32 Regulates Generation of Reactive Astrocytes in Experimental Autoimmune Encephalomyelitis. <i>Frontiers in Immunology</i> , 2020, 11, 608294.	2.2	4
119	Translational Characterization of the Glia Role in Multiple Sclerosis. <i>Neuromethods</i> , 2021, , 61-76.	0.2	2
120	Structural and Functional Neuroimaging in Multiple Sclerosis: From Atrophy, Lesions to Global Network Disruption. , 2018, , 171-213.		1
121	Latency of Multifocal Visual Evoked Potential in Multiple Sclerosis: A Visual Pathway Biomarker for Clinical Trials of Remyelinating Therapies. <i>Journal of Clinical Neurophysiology</i> , 2021, 38, 186-191.	0.9	8
122	TNFR2 limits proinflammatory astrocyte functions during EAE induced by pathogenic DR2b-restricted T cells. <i>JCI Insight</i> , 2019, 4, .	2.3	13
123	Lack of astrocytes hinders parenchymal oligodendrocyte precursor cells from reaching a myelinating state in osmolyte-induced demyelination. <i>Acta Neuropathologica Communications</i> , 2020, 8, 224.	2.4	14
124	Plasma metabolome and skin proteins in Charcot-Marie-Tooth 1A patients. <i>PLoS ONE</i> , 2017, 12, e0178376.	1.1	16
125	Astrocyte phenotypes: Emphasis on potential markers in neuroinflammation. <i>Histology and Histopathology</i> , 2021, 36, 267-290.	0.5	7
126	Targeting S100B Protein as a Surrogate Biomarker and its Role in Various Neurological Disorders. <i>Current Neuropharmacology</i> , 2020, 19, 265-277.	1.4	29



#	ARTICLE	IF	CITATIONS
127	Prevention of Brain Hypoperfusion-Induced Neurodegeneration in Rat's Hippocampus by Black Cumin Fixed Oil Treatment. <i>IUM Medical Journal Malaysia</i> , 2018, 17, .	0.1	1
128	Tenovin-1 Induces Senescence and Decreases Wound-Healing Activity in Cultured Rat Primary Astrocytes. <i>Biomolecules and Therapeutics</i> , 2019, 27, 283-289.	1.1	11
129	Role of nuclear factor $\kappa$ B in multiple sclerosis and experimental autoimmune encephalomyelitis. <i>Neural Regeneration Research</i> , 2018, 13, 1507.	1.6	55
130	Temporal and spatial evolution of various functional neurons during demyelination induced by cuprizone. <i>Journal of Neurophysiology</i> , 2021, 126, 1756-1771.	0.9	2
131	Astrocytic YAP prevents the demyelination through promoting expression of cholesterol synthesis genes in experimental autoimmune encephalomyelitis. <i>Cell Death and Disease</i> , 2021, 12, 907.	2.7	14
132	B Cell-based Therapies for Multiple Sclerosis. <i>RSC Drug Discovery Series</i> , 2019, , 134-169.	0.2	1
133	Sulfonylurea Receptor 1 in Central Nervous System Injury: An Updated Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11899.	1.8	22
135	The Histamine and Multiple Sclerosis Alliance: Pleiotropic Actions and Functional Validation. <i>Current Topics in Behavioral Neurosciences</i> , 2021, , 217-239.	0.8	4
136	The effects of mesenchymal stem cells transplantation on A1 neurotoxic reactive astrocyte and demyelination in the cuprizone model. <i>Journal of Molecular Histology</i> , 2022, , 1.	1.0	11
137	2-Chlorodeoxyadenosine (Cladribine) preferentially inhibits the biological activity of microglial cells. <i>International Immunopharmacology</i> , 2022, 105, 108571.	1.7	8
138	Molecular Mechanisms of Immunosenescence and Inflammaging: Relevance to the Immunopathogenesis and Treatment of Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2021, 12, 811518.	1.1	16
139	Endocannabinoid Modulation in Neurodegenerative Diseases: In Pursuit of Certainty. <i>Biology</i> , 2022, 11, 440.	1.3	13
140	Newly Identified Deficiencies in the Multiple Sclerosis Central Nervous System and Their Impact on the Remyelination Failure. <i>Biomedicines</i> , 2022, 10, 815.	1.4	3
141	Hearing loss among patients with multiple sclerosis (PwMS): A systematic review and meta-analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 62, 103754.	0.9	3
142	Long-term Effect of Permanent Demyelination on Axonal Survival in Multiple Sclerosis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022, 9, .	3.1	5
143	Functions of astrocytes in multiple sclerosis: A review. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 60, 103749.	0.9	8
144	Astroglial and oligodendroglial markers in the cuprizone animal model for de- and remyelination. <i>Histochemistry and Cell Biology</i> , 2022, 158, 15-38.	0.8	12
145	The matrine derivate MASM inhibits astrocyte reactivity and alleviates experimental autoimmune encephalomyelitis in mice. <i>International Immunopharmacology</i> , 2022, 108, 108771.	1.7	0

#	ARTICLE	IF	CITATIONS
146	Treatment of Experimental Autoimmune Encephalomyelitis using AAV Gene Therapy by blocking T-cell Costimulatory Pathways. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, , .	1.8	2
147	Focus on the Role of the NLRP3 Inflammasome in Multiple Sclerosis: Pathogenesis, Diagnosis, and Therapeutics. <i>Frontiers in Molecular Neuroscience</i> , 2022, 15, .	1.4	17
148	Astrocyte depletion alters extracellular matrix composition in the demyelinating phase of Theilerâ€™s murine encephalomyelitis. <i>PLoS ONE</i> , 2022, 17, e0270239.	1.1	6
149	Therapeutic Potential of Astrocyte Transplantation. <i>Cell Transplantation</i> , 2022, 31, 096368972211054.	1.2	13
150	In focus in HCB. <i>Histochemistry and Cell Biology</i> , 2022, 158, 1-4.	0.8	1
151	Potential Utility of Natural Products against Oxidative Stress in Animal Models of Multiple Sclerosis. <i>Antioxidants</i> , 2022, 11, 1495.	2.2	7
152	CTGF/CCN2 has a possible detrimental role in the inflammation and the remyelination failure in the early stages of multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2022, 371, 577936.	1.1	1
153	Role of RGC-32 in multiple sclerosis and neuroinflammation â€“ few answers and many questions. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
154	Mechanisms of Neurodegeneration in Multiple Sclerosis. <i>Zhurnal Nevrologii I Psikhatrii Imeni S S Korsakova</i> , 2022, 122, 5.	0.1	1
155	The Translatability of Multiple Sclerosis Animal Models for Biomarkers Discovery and Their Clinical Use. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11532.	1.8	13
156	Bu Shen Yi Sui Capsule Promotes Myelin Repair by Modulating the Transformation of A1/A2 Reactive Astrocytes In Vivo and In Vitro. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-22.	1.9	10
157	Combination Therapy of Mesenchymal Stem Cell Transplantation and Astrocyte Ablation Improve Remyelination in a Cuprizone-Induced Demyelination Mouse Model. <i>Molecular Neurobiology</i> , 2022, 59, 7278-7292.	1.9	4
158	The regulatory role of NLRX1 in innate immunity and human disease. <i>Cytokine</i> , 2022, 160, 156055.	1.4	5
159	Emodin attenuates inflammation and demyelination in experimental autoimmune encephalomyelitis. <i>Neural Regeneration Research</i> , 2023, 18, 1535.	1.6	5
160	Impact of the Renin-Angiotensin System on the Pathogeny and Pharmacotherapeutics of Neurodegenerative Diseases. <i>Biomolecules</i> , 2022, 12, 1429.	1.8	4
161	Phloretin enhances remyelination by stimulating oligodendrocyte precursor cell differentiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	4
162	Multiple sclerosis progression: time for a new mechanism-driven framework. <i>Lancet Neurology</i> , The, 2023, 22, 78-88.	4.9	113
163	Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2023, 94, 1-9.	0.9	9

#	ARTICLE	IF	CITATIONS
164	Cathepsin-B inhibitor CA-074 attenuates retinopathy and optic neuritis in experimental autoimmune encephalomyelitis induced in SJL/J mice. Saudi Pharmaceutical Journal, 2023, 31, 147-153.	1.2	1
165	Neuroaxonal and Glial Markers in Patients of the Same Age With Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2023, 10, .	3.1	6
166	Cerebrospinal fluid immunoglobulins in primary progressive multiple sclerosis are pathogenic. Brain, 2023, 146, 1979-1992.	3.7	4
167	Interpretable and context-free deconvolution of multi-scale whole transcriptomic data with UniCell deconvolve. Nature Communications, 2023, 14, .	5.8	10
168	Platelets and platelet-derived vesicles as an innovative cellular and subcellular platform for managing multiple sclerosis. Molecular Biology Reports, 2023, 50, 4675-4686.	1.0	3
170	Space Renaissance and Neurodegeneration. , 2022, , 123-132.		0
174	The molecular pathology of neurodegenerative and psychiatric disorders. , 2023, , 3-43.		4
176	The role of stress in mediating inflammation in the context of neurodegeneration. , 2024, , 325-337.		0